https://journals.bohrpub.com/index.php/bijops <p><strong>ISSN: 2583-9373 (Online)</strong></p> <p><strong>BOHR Journal of Pharmaceutical Studies (BJOPS) </strong>is a peer reviewed open-access journal dedicated to fostering innovation and advancing knowledge in the field of Pharmaceutical Studies. Our journal aims to provide a forum for researchers, clinicians, and professionals to share their insights, discoveries, and advancements in various topics of Pharmaceutical Studies. Authors are solicited to contribute to the journal by submitting articles that illustrate high-quality research and contributes to the understanding, diagnosis, treatment, and prevention of diseases.</p> en-US BOHR Journal of Pharmaceutical Studies <p>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a <a href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</a> that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.</p> https://journals.bohrpub.com/index.php/bijops/article/view/905 <p>High-concentration monoclonal antibody (mAb) formulations have become essential for subcutaneous (SC) administration, enabling patient-centric dosing and reducing healthcare burden. However, achieving concentrations above 100–150 mg/mL presents multifactorial challenges, including steep viscosity increases, reversible self-association, opalescence, aggregation, and chemical degradation pathways that complicate manufacturability, stability, and device compatibility. Molecular determinants of rheology—electrostatics, hydrophobic surface patches, aromatic/cation–π interactions, glycosylation, and structural architecture—are further modulated by excipients, solvent structuring, and crowding effects. Advances in biophysical screening (DLS/SLS, SV-AUC, microrheology), predictive analytics, and machine learning models now allow earlier identification of viscosity liabilities, though validation under device-relevant shear conditions remains critical. Mitigation strategies include solution conditioning, excipient innovation, protein engineering, and optimized processing/presentation formats, supported by risk-based controls for excipient degradation and container–closure interactions. Co-optimization of rheology with device mechanics has enabled successful marketed products, while recombinant human hyaluronidase PH20 (rHuPH20)-facilitated large-volume SC (LVSC) delivery expands dosing feasibility. Embedding these efforts within a Quality by Design (QbD) framework—linking QTPP to CQAs, CMAs, CPPs, and design space verification—ensures robust product development. Case studies of trastuzumab, rituximab, daratumumab, adalimumab, tocilizumab, and pertuzumab/trastuzumab illustrate how formulation and device innovation converge to deliver high-concentration SC biologics. Looking forward, integration of novel excipients, AI/ML-based developability tools, and advanced delivery systems will accelerate development, reduce iteration cycles, and support next-generation patient-friendly antibody therapies.</p> Priya Patel Vaibhav Bhatt Nirav Patel Copyright (c) 2026 Priya Patel, Vaibhav Bhatt, Nirav Patel https://creativecommons.org/licenses/by/4.0 2026-05-26 2026-05-26 4 1 10 28 10.54646/BJOPS.2026.20 https://journals.bohrpub.com/index.php/bijops/article/view/1011 <p>Herbal plants have gained prominence in the field of oral hygiene and care because of their inherent properties, such as being antimicrobial, anti-inflammatory, and anti-oxidant. This review aims to focus on some of the prominent herbs such as neem, clove, timur, and tulsi, along with some other medicinal plants, and their potential in treating some of the commonly encountered oral health issues such as plaque, gingivitis, and microbial infections. These herbs contain active ingredients such as flavonoids, tannins, terpenoids, and essential oils, which contribute to their medicinal properties. Various herbal formulations, such as mouthwashes, toothpastes, and gels, have shown promising benefits, making them safer alternatives to chemical-based ingredients. Although a number of studies have shown positive results, more research is warranted to validate their safety profile and efficacy.</p> Deepa Nagendra Bisht Amar Kumar Riya Jaiswal Copyright (c) 2026 Deepa, Nagendra Bisht, Amar Kumar, Riya Jaiswal https://creativecommons.org/licenses/by/4.0 2026-05-02 2026-05-02 4 1 1 9 10.54646/BJOPS.2026.19